BioSpace News Archive

The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligo Meeting.

Wellcome and the Bill & Melinda Gates Foundation announced funding to advance a tuberculosis vaccine candidate, M72/AS01E, through a Phase III clinical trial.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it has closed the sale of 3,362,833 Units at a subscription price of $0.12 per Unit for gross proceeds of $403,539.96.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that PreveCeutical is furthering the progress of two of its patent families.

71% of cancer deaths in the United States are caused by cancers without recommended screenings.

AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (Together AusperBio), a clinical-stage biotech company announced that the Center for Drug Evaluation (CDE) of China has approved the Investigational New Drug (IND) application of AHB-137 to treat chronic hepatitis B (CHB) aiming for functional cure.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29th.

ImmuCell Corporation announced a change to its anticipated FDA submission schedule.

McKesson Corporation (NYSE: MCK) will release its first-quarter fiscal 2024 financial results after market close on Wednesday, August 2, 2023.

Aethlon Medical, Inc., a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, reported financial results for its fiscal year ended March 31, 2023 and provided an update on recent developments.